eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
5/2001
vol. 5
 
Share:
Share:
abstract:

Myeloma bone disease

Jan Maciej Zaucha

Współcz Onkol (2001) vol. 5, 5 (195-196)
Online publish date: 2003/07/18
View full text Get citation
 
New insights in the pathophysiology of myeloma bone disease are discussed. Bone disease is the major manifestation of myeloma multiplex. The presence of myeloma cells disturbs the delicate balance between osteolysis and osteosynthesis. Myeloma cells stimulate osteolysis directly through the production of TRANCE/RANKL molecule, which physiologically activates osteoclasts and indirectly through the production of syndecan-1 (CD138), which inhibits osteprotegerin, which in turn acts as a decoy receptor for TRANCE/RANKL. Increased osteoclastic activity leads to release from the bone marrow matrix of several cytokines, which stimulate myloma cells growth. Biphosphonates decrease the incidence and severity of bone lesions, however they do not prolong overall survival.
keywords:

Myeloma multiplex, myeloma bone disease

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.